|
Schirdewan博士的引述的參考文獻:
a# S1 A$ L }1 Z. \. s6 c/ ?5 m/ U' i
Camm, AJ et al., Remote control of implanted devices through Home Monitoring technology improves detection and clinical management of atrial fibrillation (透過Home Monitoring技術遠距控制植入式裝置可改進房顫的檢測和臨床管理), Europace, 11(1):54–61, 2009. * n. m3 ?( s. A' _2 A, q* c0 |
' ^# W8 m, e4 |/ p" E& qDaubert, JP et al., Inappropriate implantable cardioverter-defibrillator shocks in MADIT-II (MADIT-II中植入式心臟複律去顫器不合時宜的電擊), JACC, 51:1357–65, 2008
J* E" [' q/ L) `/ l' n: G3 T- a- B: h, |
Ricci, RP et al., Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) (心房顫動管理指南:歐洲心臟學會心房顫動管理工作小組), Europace, 12(10):1360–1420, 2010. 7 {# c0 {! k% z1 r: G
- O2 L1 `/ o6 i$ L5 s0 I$ _
關於BIOTRONIK SE & Co. KG5 h& M/ i+ V4 M! r, e( Y5 l" S
% j/ i% K' t5 V% ?$ k2 Y
BIOTRONIK公司是世界領先的心血管醫療器材製造商之一,已售出數百萬台植入式裝置,全球員工超過5600位,業務遍及100多個國家。BIOTRONIK公司密切感知醫療界的脈動、評估醫生面臨的挑戰,從診斷、治療到患者管理,為患者醫護的所有階段提供最佳解決方案。BIOTRONIK公司及其不斷成功的理念在於品質、創新和可靠性,從而為全球醫生及其患者帶來信心和安心。進一步資訊請瀏覽: www.biotronik.com |
|